| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Deanna L Kelly, Robert R Conle. Thyroid function in treatment-resistant schizophrenia patients treated with quetiapine, risperidone, or fluphenazine. The Journal of clinical psychiatry. vol 66. issue 1. 2005-02-24. PMID:15669892. |
thyroid function in treatment-resistant schizophrenia patients treated with quetiapine, risperidone, or fluphenazine. |
2005-02-24 |
2023-08-12 |
Not clear |
| Richard C Josiassen, Ashok Joseph, Eva Kohegyi, Sudhir Stokes, Mahmood Dadvand, Wynn Wynn Paing, Rita A Shaughness. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. The American journal of psychiatry. vol 162. issue 1. 2005-02-18. PMID:15625211. |
clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. |
2005-02-18 |
2023-08-12 |
Not clear |
| Richard C Josiassen, Ashok Joseph, Eva Kohegyi, Sudhir Stokes, Mahmood Dadvand, Wynn Wynn Paing, Rita A Shaughness. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. The American journal of psychiatry. vol 162. issue 1. 2005-02-18. PMID:15625211. |
the authors evaluated the efficacy and safety of augmenting clozapine with risperidone in patients with treatment-resistant schizophrenia. |
2005-02-18 |
2023-08-12 |
Not clear |
| Michael Ritsner, Anatoly Gibel, Galina Perelroyzen, Rena Kurs, Mahmoud Jabarin, Yael Ratne. Quality of life outcomes of risperidone, olanzapine, and typical antipsychotics among schizophrenia patients treated in routine clinical practice: a naturalistic comparative study. Journal of clinical psychopharmacology. vol 24. issue 6. 2005-02-16. PMID:15538118. |
quality of life outcomes of risperidone, olanzapine, and typical antipsychotics among schizophrenia patients treated in routine clinical practice: a naturalistic comparative study. |
2005-02-16 |
2023-08-12 |
Not clear |
| Michael Ritsner, Anatoly Gibel, Galina Perelroyzen, Rena Kurs, Mahmoud Jabarin, Yael Ratne. Quality of life outcomes of risperidone, olanzapine, and typical antipsychotics among schizophrenia patients treated in routine clinical practice: a naturalistic comparative study. Journal of clinical psychopharmacology. vol 24. issue 6. 2005-02-16. PMID:15538118. |
to test this assumption in a naturalistic cross-sectional design, we evaluated general and domain-specific qol scores for baseline data of schizophrenia outpatients stabilized on atypical (n = 78, risperidone or olanzapine) and typical (n = 55) agents. |
2005-02-16 |
2023-08-12 |
Not clear |
| Donald E N Addington, Christos Pantelis, Mary Dineen, Isma Benattia, Steven J Roman. Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial. The Journal of clinical psychiatry. vol 65. issue 12. 2005-02-07. PMID:15641867. |
efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial. |
2005-02-07 |
2023-08-12 |
Not clear |
| Donald E N Addington, Christos Pantelis, Mary Dineen, Isma Benattia, Steven J Roman. Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial. The Journal of clinical psychiatry. vol 65. issue 12. 2005-02-07. PMID:15641867. |
thus, we compared ziprasidone and risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder. |
2005-02-07 |
2023-08-12 |
Not clear |
| Jeffrey W Swanson, Marvin S Swartz, Eric B Elbogen, Richard A Van Dor. Reducing violence risk in persons with schizophrenia: olanzapine versus risperidone. The Journal of clinical psychiatry. vol 65. issue 12. 2005-02-07. PMID:15641872. |
reducing violence risk in persons with schizophrenia: olanzapine versus risperidone. |
2005-02-07 |
2023-08-12 |
Not clear |
| Jeffrey W Swanson, Marvin S Swartz, Eric B Elbogen, Richard A Van Dor. Reducing violence risk in persons with schizophrenia: olanzapine versus risperidone. The Journal of clinical psychiatry. vol 65. issue 12. 2005-02-07. PMID:15641872. |
this study prospectively examined the effectiveness of treatment with olanzapine versus risperidone in reducing violent behavior among patients with schizophrenia under "usual care" conditions in the community. |
2005-02-07 |
2023-08-12 |
Not clear |
| David E Moody, John D Laycock, Wei Huang, Rodger L Folt. A high-performance liquid chromatographic-atmospheric pressure chemical ionization-tandem mass spectrometric method for determination of risperidone and 9-hydroxyrisperidone in human plasma. Journal of analytical toxicology. vol 28. issue 6. 2005-02-04. PMID:15516302. |
risperidone, a benzisoxazole derivative, is an antipsychotic agent used for the treatment of schizophrenia. |
2005-02-04 |
2023-08-12 |
human |
| Kate McKeage, Greg L Ploske. Amisulpride: a review of its use in the management of schizophrenia. CNS drugs. vol 18. issue 13. 2005-02-04. PMID:15521794. |
amisulpride (200-1200 mg/day) was at least as effective as haloperidol and as effective as risperidone or olanzapine, in studies of up to 1 year in patients with schizophrenia manifesting predominantly positive symptoms. |
2005-02-04 |
2023-08-12 |
Not clear |
| Kate McKeage, Greg L Ploske. Amisulpride: a review of its use in the management of schizophrenia. CNS drugs. vol 18. issue 13. 2005-02-04. PMID:15521794. |
in conclusion, oral amisulpride (200-1200 mg/day) is at least as effective as haloperidol, and as effective as risperidone or olanzapine, in the treatment of patients with schizophrenia manifesting predominantly positive symptoms. |
2005-02-04 |
2023-08-12 |
Not clear |
| A Leal, D Rosillon, A Mehnert, M Jarema, G Remingto. Healthcare resource utilization during 1-year treatment with long-acting, injectable risperidone. Pharmacoepidemiology and drug safety. vol 13. issue 11. 2005-02-02. PMID:15386706. |
this study assessed healthcare resource use in patients with schizophrenia and schizoaffective disorder during treatment with long-acting risperidone. |
2005-02-02 |
2023-08-12 |
Not clear |
| Josephine F Reyes, Sheldon H Preskorn, Ahsan Khan, Dinesh Kumar, Edward I Cullen, Carlos A Perdomo, Raymond D Prat. Concurrent administration of donepezil HCl and risperidone in patients with schizophrenia: assessment of pharmacokinetic changes and safety following multiple oral doses. British journal of clinical pharmacology. vol 58 Suppl 1. 2005-02-02. PMID:15496223. |
concurrent administration of donepezil hcl and risperidone in patients with schizophrenia: assessment of pharmacokinetic changes and safety following multiple oral doses. |
2005-02-02 |
2023-08-12 |
Not clear |
| Megan J Ehret, Matthew A Fulle. Long-acting injectable risperidone. The Annals of pharmacotherapy. vol 38. issue 12. 2005-01-31. PMID:15522979. |
to review the pharmacology, pharmacokinetics, clinical efficacy, and safety profile of long-acting (la) risperidone for the treatment of schizophrenia. |
2005-01-31 |
2023-08-12 |
Not clear |
| Dan W Haupt, Angela Luber, Justin Maeda, Angela K Melson, Julie A Schweiger, John W Newcome. Plasma leptin and adiposity during antipsychotic treatment of schizophrenia. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 30. issue 1. 2005-01-26. PMID:15367925. |
plasma leptin was measured in 72 schizophrenia patients chronically treated with olanzapine (n=27), risperidone (n=24) or typical antipsychotics (n=21) and 124 healthy adult control subjects. |
2005-01-26 |
2023-08-12 |
human |
| Samuel J Keith, Luca Pani, Beat Nick, Robin Emsley, Luis San, Martin Turner, Robert Conley, Paul Scully, Pierre S Chue, Bernard Lachau. Practical application of pharmacotherapy with long-acting risperidone for patients with schizophrenia. Psychiatric services (Washington, D.C.). vol 55. issue 9. 2005-01-24. PMID:15345759. |
practical application of pharmacotherapy with long-acting risperidone for patients with schizophrenia. |
2005-01-24 |
2023-08-12 |
Not clear |
| Pierre Chue, Ron Welch, Carin Binde. Acceptability and disintegration rates of orally disintegrating risperidone tablets in patients with schizophrenia or schizoaffective disorder. Canadian journal of psychiatry. Revue canadienne de psychiatrie. vol 49. issue 10. 2005-01-11. PMID:15560318. |
acceptability and disintegration rates of orally disintegrating risperidone tablets in patients with schizophrenia or schizoaffective disorder. |
2005-01-11 |
2023-08-12 |
Not clear |
| Pierre Chue, Ron Welch, Carin Binde. Acceptability and disintegration rates of orally disintegrating risperidone tablets in patients with schizophrenia or schizoaffective disorder. Canadian journal of psychiatry. Revue canadienne de psychiatrie. vol 49. issue 10. 2005-01-11. PMID:15560318. |
to investigate the disintegration profile, acceptability, and tolerability of orally disintegrating risperidone tablets in patients with schizophrenia or schizoaffective disorder. |
2005-01-11 |
2023-08-12 |
Not clear |
| Hidehisa Yamashita, Kazuhiko Mori, Masatsugu Nagao, Yasumasa Okamoto, Shigeru Morinobu, Shigeto Yamawak. Effects of changing from typical to atypical antipsychotic drugs on subjective sleep quality in patients with schizophrenia in a Japanese population. The Journal of clinical psychiatry. vol 65. issue 11. 2004-12-21. PMID:15554767. |
to investigate the effects of the atypical antipsychotic drugs risperidone, olanzapine, quetiapine, and perospirone on the subjective quality of sleep in patients with schizophrenia. |
2004-12-21 |
2023-08-12 |
Not clear |